MAP2K1 and serous adenocarcinoma: Selumetinib, a MEK1/2 inhibitor, demonstrates promising efficacy in women with relapsed low-grade serous carcinoma, and further trials of MEK-inhibition are underway (McLachlan et al., 2016).